CN Patent

CN102372691A — (r)-3-苯二甲酰亚胺哌啶酒石酸盐的制备工艺

Assigned to Wisdom Pharmaceutical Co Ltd · Expires 2012-03-14 · 14y expired

What this patent protects

本发明涉及利拉利汀关键中间体( R )-3-苯二甲酰亚胺哌啶酒石酸盐的合成新工艺。( R )-3-氨基哌啶盐酸盐在碱作用下和邻苯二甲酸酐进行缩合，高产率的制备( R )-3-苯二甲酰亚胺哌啶,后者方便简单地和D-(-)-酒石酸成盐从而完成( R )-3-苯二甲酰亚胺哌啶酒石酸的制备。本发明各步的原材料价格较低、各步骤单元操作简单、设备要求低、安全性高，后处理及纯化操作简单，适合工业化大生产。

USPTO Abstract

本发明涉及利拉利汀关键中间体( R )-3-苯二甲酰亚胺哌啶酒石酸盐的合成新工艺。( R )-3-氨基哌啶盐酸盐在碱作用下和邻苯二甲酸酐进行缩合，高产率的制备( R )-3-苯二甲酰亚胺哌啶,后者方便简单地和D-(-)-酒石酸成盐从而完成( R )-3-苯二甲酰亚胺哌啶酒石酸的制备。本发明各步的原材料价格较低、各步骤单元操作简单、设备要求低、安全性高，后处理及纯化操作简单，适合工业化大生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN102372691A
Jurisdiction
CN
Classification
—
Expires
2012-03-14
Drug substance claim
No
Drug product claim
No
Assignee
Wisdom Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.